Onkologie. 2013:7(4):176-178

Colorectal cancer screening

Štěpán Suchánek1, Tomáš Grega1, Ondřej Májek2, Ladislav Dušek2, Miroslav Zavoral1
1 Interní klinika, 1. LF UK, ÚVN &ndash, VFN Praha
2 Institut biostatistiky a analýz Masarykovy Univerzity, Brno

Colorectal cancer is the second most common malignant disease in developed countries. Given that the process of sporadic cancer carcinogenesis

is relatively slow, it is possible to successfully prevent this disease. Czech National Colorectal Cancer Screening Program was

launched in 2000 and since that time is in continual development in order to increase the effective coverage of the target population. It

is currently available as two-step screening program (stool test for occult blood and colonoscopy) or one-step program (primary screening

colonoscopy). Quality of the program is evaluated using performance indicators – namely adenoma detection rate (ADR) and cecal

intubation rate (CIR). The screening program in the Czech Republic enables long-term stabilization of incidence and a slight decrease

in mortality from colorectal cancer. To further reduce the incidence and mortality of this disease, greater participation of the target

population using personalized invitation of target population and media campaigns are necessary.

Keywords: colorectal cancer, screening, fecal occult blood test, colonoscopy, quality control

Published: October 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchánek Š, Grega T, Májek O, Dušek L, Zavoral M. Colorectal cancer screening. Onkologie. 2013;7(4):176-178.
Download citation

References

  1. The Global Economy Cost of Cancer, American cancer society 2010, www.cancer.org.
  2. Ferlay J, Shin HR, Bray F, et al. Cancer Incidence and Mortality. Worldwide & International Agency for Research on Cancer 2010; http://globocan.iarc.fr.
  3. Fric P, Zavoral M, Dvorakova H. An adapted program of colorectal cancer screening-7 years experience and cost-benefit analysis. Hepatogastroenterology 1994; 41 (5): 413-416. Go to PubMed...
  4. Frič P, Zavoral M, Čekal J, et al. Screening kolorektálního karcinomu v současném systému zdravotní péče. Endoskopie 1999; 8: 39-45.
  5. Zavoral M., Závada F, Šálek C, Frič P. Czech Society of Gastroenterology: Colorectal Cancer Screening in the Czech Republic. Endoscopy 2006; 38 (5): 550-551.
  6. La Vecchia C. Fecal occult blood screening for colorectal cancer: open issues. Ann Oncol. 2002, 13 (1): 31-4. Go to original source... Go to PubMed...
  7. Jouve JL, Remontet L, Dancourt V, et al. Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening 2001; 84 (11): 1477-81. Go to original source...
  8. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med. 2009; 150(3): 162-169. Go to original source... Go to PubMed...
  9. Zavoral M, Suchanek S, Zavada F, et al. Colorectal cancer screening in Europe. J Gastroenterology 2009; 47 (15): 5907-5915. Go to original source... Go to PubMed...
  10. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice 2005; www.svod.cz.
  11. Věstník Ministerstva zdravotnictví České republiky, ročník 2009; 1.
  12. Singh R, Bourke MJ, Jayanna M, et al. Colon tumors and colonoscopy. Gastrointestinal Endoscopy 2012; 76 (3): 525-530. Go to original source... Go to PubMed...
  13. Segnan N, Patnick J, von Karsa L. European guidelines for quality assurance in colorectal cancer screening and diagnosis, 1st ed., European Union, 2010: 274-297.




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.